patient is waiting

In this week’s update: Brexit Medicine regulation implications, General election update, Japanese delegation and SIAC clinical research meeting

Mixed messaging on what Brexit will mean for the future regulation of medicines last week. On the one hand the UK government (answering a question in the UK parliament) hinted that it hoped for “continued cooperation in the field of medicine regulation in the best interest of both the UK and the EU”, on the other the EMA put out a bold statement following its management board saying that it is working  “on the basis of the scenario that foresees that the UK will no longer participate in the work of EMA and the European medicines regulatory system as of 30 March 2019.” I’ll update further, with my interpretation, on Friday’s webinar on Brexit and the UK general Election – click here to register. If you want even more on this it will also be a core discussion at our Regulatory conference on June 8thclick here to register.

As the UK General Election gets into full swing, the BIA published a new report on Friday, aimed at the political parties as they prepare their manifestos arguing that without lasting political commitment, the momentum of the UK’s life sciences industry will be lost. The BIA is using Now More Than Ever: Seizing the opportunity to make the UK a world leader in the life sciences, to call on political parties to turn warm words into practical solutions to strengthen UK life sciences. In particular, parties should think creatively about how to harness the unique strengths of the NHS, as a single integrated system, to bolster UK life sciences in the face of global competition for investment. Over 3 years of policy work, through 3 administrations have gone into the development of Accelerated Access policy proposals. 2017 is the time for action. To give confidence to life science investment into the UK, the BIA is asking all political parties contesting the forthcoming General Election to commit to ensuring the AAR recommendations are adopted in their health manifestos and delivered in the next parliament.

It was great that Conservative BEIS Spokesman Greg Clark and Labour’s Chi Onwurah accepted my invitation (made at the ABPI conference) to come and visit the UK vibrant life science sector during the campaign – we are working on details of that visit this week. For more on what we’ve done recently, check out the BIA Q1 report.

On Wednesday, we were visited by a Japanese Government and industry delegation who were over in the UK to learn about our world-leading synthetic biology industry. They were keen to understand how the UK has established itself in this exciting technology field through an active industrial strategy and how the BIA’s Engineering Biology Advisory Committee has supported that process.

BIA’s newest committee, the Science and Innovation Advisory Committee, held a joint workshop with the Faculty of Pharmaceutical Medicine on Thursday to discuss possible options to remove barriers and facilitate expedited clinical research for the benefit of patients. The challenges of precision oncology drug development, innovations to expedite clinical development and recent developments in clinical trial regulations were discussed. The recommendations identified to facilitate early access to promising medicines will be fed into the Life Science Industrial Strategy.

Finally our CEO and Investor Forum is only 4 weeks away now and we have a great community coming together on the evening of May 24 and the day of May 25th in Oxford – do check out the agenda and I hope you can join us.

Best, Steve